The charts on this page feature a breakdown of the total annual pay for the top executives at MYRIAD GENETICS INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. MYRIAD GENETICS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. MYRIAD GENETICS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Mark C. Capone
Former President and Chief Executive Officer and Director
Total Cash $1,054,771 Equity $4,489,500 Other $630,187 Total Compensation $6,174,458
Jerry S. Lanchbury Ph.D.
Chief Scientific Officer
Total Cash $625,095 Equity $1,197,200 Other $6,943 Total Compensation $1,829,238
R. Bryan Riggsbee
Chief Financial Officer and Treasurer; Interim President and Chief Executive Officer
Total Cash $733,005 Equity $3,461,500 Other $8,836 Total Compensation $4,203,341
Bernard F. Tobin
Former President of Myriad Autoimmune
Total Cash $526,458 Equity $1,047,550 Other $305,037 Total Compensation $1,879,045
Alexander Ford
Former Chief Operating Officer
Total Cash $663,914 Equity $1,496,500 Other $22,629 Total Compensation $2,183,043
Gary A. King
Former Executive Vice President International Operations
Total Cash $513,918 Equity $808,110 Other $639,131 Total Compensation $1,961,159
Nicole Lambert
Group President of Myriad Women's Health, Oncology, and International
Total Cash $486,793 Equity $1,197,200 Other $20,713 Total Compensation $1,704,706
Mark Verratti
Group President of Myriad Neuroscience and Autoimmune
Total Cash $0 Equity $0 Other $0 Total Compensation $0
Paul J. Diaz
President and Chief Executive Officer
Total Cash $0 Equity $0 Other $0 Total Compensation $0
For its 2020 fiscal year, MYRIAD GENETICS INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Colleen F. Reitan Total Cash $356,484
Daniel K. Spiegelman Total Cash $359,642
Dennis H. Langer, Ph.D., J.D Total Cash $360,234
Heiner Dreismann, Ph.D. Total Cash $358,734
John T. Henderson, M.D. Total Cash $47,064
Lawrence C. Best Total Cash $44,450
Lee N. Newcomer, M.D. Total Cash $360,984
S. Louise Phanstiel Total Cash $424,734

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.